Skip to content
2000
image of Gender Differences in Efficacy and Tolerability of Opicapone in Add on of Levodopa. A Single-Center Retrospective Cohort Study
file format pdf download PDF

Abstract

Introduction

Opicapone is a peripheral catechol-O-methyltransferase inhibitor (COMT), approved an add on to levodopa in Parkinson's disease (PD) patients with motor fluctuations. We carried out a retrospective cohort study to evaluate gender differences in efficacy and tolerability of opicapone.

Methods

PD patients with motor fluctuations who started opicapone and who were followed up for at least 6 months were retrospectively enrolled. Total daily OFF (at baseline and follow-up), presence or worsening of dyskinesia, or presence of other adverse events (AE) at follow-up, were recorded.

Results

Seventy-seven PD patients (51 men; 66.2%) with a disease duration of 11.0 ± 4.2 years were enrolled. At follow-up, a significant reduction of the total daily OFF time was observed in men with PD. Overall, 41.6% of PD patients reported some AEs, of which the presence or worsening of dyskinesia was the most common. Incidence of AEs was significantly higher among women (65.4% 29.4%; -value 0.002) and at multivariate analysis, female sex was significantly associated with the presence of AEs (OR 4.08; 95% CI 1.46-11.4; -value 0.007); At 6 months 27.3% patients discontinued opicapone and women had significantly higher odds of discontinuation (OR 3.00; -value 0.04).

Discussion

Opicapone is highly effective for the treatment of motor fluctuations. The occurrence of AEs is more frequent among women may be attributed to a higher levodopa bioavailability. To avoid an early discontinuation due to AEs, levodopa dosage should be reduced in women before the introduction of opicapone.

Conclusion

Our study provides novel insights regarding gender differences in PD treatment.

© 2026 The Author(s). Published by Bentham Science Publisher.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/cn/10.2174/011570159X407015250910194113
2026-02-24
2026-03-07

  • From This Site

    /content/journals/cn/10.2174/011570159X407015250910194113
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cn/10.2174/011570159X407015250910194113/BMS-CN-2025-189.html?itemId=/content/journals/cn/10.2174/011570159X407015250910194113&mimeType=html&fmt=ahah

References

  1. Deliz J.R. Tanner C.M. Gonzalez-Latapi P. Epidemiology of Parkinson’s disease: An update. Curr. Neurol. Neurosci. Rep. 2024 24 6 163 179 10.1007/s11910‑024‑01339‑w 38642225
    [Google Scholar]
  2. Cardoso F. Tolosa E. Fluctuations in Parkinson’s disease: Progress and challenges. Lancet Neurol. 2024 23 5 448 449 10.1016/S1474‑4422(24)00116‑9 38499016
    [Google Scholar]
  3. Nicoletti A. Baschi R. Cicero C.E. Iacono S. Re V.L. Luca A. Schirò G. Monastero R. Sex and gender differences in Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis: A narrative review. Mech. Ageing Dev. 2023 212 111821 10.1016/j.mad.2023.111821 37127082
    [Google Scholar]
  4. Donzuso G. Cicero C.E. Vinciguerra E. Sergi R. Luca A. Mostile G. Terravecchia C. Zappia M. Nicoletti A. Gender differences in non-motor fluctuations in Parkinson’s disease. J. Neural Transm. 2023 130 10 1249 1257 10.1007/s00702‑023‑02679‑6 37526768
    [Google Scholar]
  5. Conti V. Izzo V. Russillo M.C. Picillo M. Amboni M. Scaglione C.L.M. Nicoletti A. Cani I. Cicero C.E. De Bellis E. Charlier B. Giudice V. Somma G. Corbi G. Barone P. Filippelli A. Pellecchia M.T. Gender differences in levodopa pharmacokinetics in Levodopa-Naïve patients with Parkinson’s disease. Front. Med. 2022 9 909936 10.3389/fmed.2022.909936 35712091
    [Google Scholar]
  6. Zappia M. Crescibene L. Arabia G. Nicoletti G. Bagalà A. Bastone L. Caracciolo M. Bonavita S. Di Costanzo A. Scornaienchi M. Gambardella A. Quattrone A. Body weight influences pharmacokinetics of levodopa in Parkinson’s disease. Clin. Neuropharmacol. 2002 25 2 79 82 10.1097/00002826‑200203000‑00004 11981233
    [Google Scholar]
  7. Müller T. Woitalla D. Saft C. Kuhn W. Levodopa in plasma correlates with body weight of parkinsonian patients. Parkinsonism Relat. Disord. 2000 6 3 171 173 10.1016/S1353‑8020(00)00005‑5 10817957
    [Google Scholar]
  8. Contin M. Lopane G. Belotti L.M.B. Galletti M. Cortelli P. Calandra-Buonaura G. Sex Is the main determinant of levodopa clinical pharmacokinetics: Evidence from a large series of levodopa therapeutic monitoring. J. Parkinsons Dis. 2022 12 8 2519 2530 10.3233/JPD‑223374 36373294
    [Google Scholar]
  9. Kumagai T. Nagayama H. Ota T. Nishiyama Y. Mishina M. Ueda M. Sex differences in the pharmacokinetics of levodopa in elderly patients with Parkinson disease. Clin. Neuropharmacol. 2014 37 6 173 176 10.1097/WNF.0000000000000051 25384078
    [Google Scholar]
  10. Fox S.H. Katzenschlager R. Lim S.Y. Barton B. de Bie R.M.A. Seppi K. Coelho M. Sampaio C. International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson’s disease. Mov. Disord. 2018 33 8 1248 1266 10.1002/mds.27372 29570866
    [Google Scholar]
  11. Rocha J.F. Falcão A. Santos A. Pinto R. Lopes N. Nunes T. Wright L.C. Vaz-da-Silva M. Soares-da-Silva P. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. Eur. J. Clin. Pharmacol. 2014 70 9 1059 1071 10.1007/s00228‑014‑1701‑2 24925090
    [Google Scholar]
  12. Ferreira JJ. Rocha JF. Falcão A. Santos A. Pinto R. Nunes T. Soares-da-Silva P. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson’s disease. Eur. J. Neurol. 2015 22 5 815 825 10.1111/ene.12666
    [Google Scholar]
  13. Postuma R.B. Berg D. Stern M. Poewe W. Olanow C.W. Oertel W. Obeso J. Marek K. Litvan I. Lang A.E. Halliday G. Goetz C.G. Gasser T. Dubois B. Chan P. Bloem B.R. Adler C.H. Deuschl G. MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord. 2015 30 12 1591 1601 10.1002/mds.26424 26474316
    [Google Scholar]
  14. Goetz C.G. Tilley B.C. Shaftman S.R. Stebbins G.T. Fahn S. Martinez-Martin P. Poewe W. Sampaio C. Stern M.B. Dodel R. Dubois B. Holloway R. Jankovic J. Kulisevsky J. Lang A.E. Lees A. Leurgans S. LeWitt P.A. Nyenhuis D. Olanow C.W. Rascol O. Schrag A. Teresi J.A. van Hilten J.J. LaPelle N. Movement Disorder Society‐sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results. Mov. Disord. 2008 23 15 2129 2170 10.1002/mds.22340 19025984
    [Google Scholar]
  15. Schade S. Mollenhauer B. Trenkwalder C. Levodopa equivalent dose conversion factors: An updated proposal including opicapone and safinamide. Mov. Disord. Clin. Pract. 2020 7 3 343 345 10.1002/mdc3.12921 32258239
    [Google Scholar]
  16. Ferreira J.J. Lees A. Rocha J.F. Poewe W. Rascol O. Soares-da-Silva P. Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: A randomised, double-blind, controlled trial. Lancet Neurol. 2016 15 2 154 165 10.1016/S1474‑4422(15)00336‑1 26725544
    [Google Scholar]
  17. Lees AJ. Ferreira J. Rascol O. Poewe W. Rocha JF. McCrory M Soares-da-Silva P. Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: A randomized clinical trial. JAMA Neurology 2017 74 2 197 206 10.1001/jamaneurol.2016.4703
    [Google Scholar]
  18. Bacchin R. Liccari M. Catalan M. Antonutti L. Manganotti P. Malaguti M.C. Giometto B. Disease stage and motor fluctuation duration predict drug tolerability: A real-life, prospective Italian multicenter study on the use of opicapone in Parkinson’s disease. Drugs Real World Outcomes 2024 11 3 361 368 10.1007/s40801‑024‑00442‑1 38954191
    [Google Scholar]
  19. Rocha J.F. Ebersbach G. Lees A. Tolosa E. Ferreira J.J. Poewe W. Rascol O. Stocchi F. Antonini A. Magalhães D. Gama H. Soares-da-Silva P. The safety/tolerability of opicapone when used early in Parkinson’s disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II. Front. Neurol. 2022 13 994114 10.3389/fneur.2022.994114 36081875
    [Google Scholar]
  20. Arabia G. Zappia M. Bosco D. Crescibene L. Bagalà A. Bastone L. Caracciolo M. Scornaienghi M. Quattrone A. Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson’s disease. Neurol. Sci. 2002 23 Suppl. 2 S53 S54 10.1007/s100720200066 12548340
    [Google Scholar]
  21. Nishikawa N. Iwaki H. Shiraishi T. Mukai Y. Takahashi Y. Murata M. Female, aging, difference formulations of DCI, or lower body weight increases AUC4hr of levodopa in patients with Parkinson’s disease. Parkinsonism Relat. Disord. 2020 76 16 20 10.1016/j.parkreldis.2020.05.020 32554330
    [Google Scholar]
  22. Ferreira J.J. Poewe W. Rascol O. Stocchi F. Antonini A. Moreira J. Guimarães B. Rocha J.F. Soares-da-Silva P. Effect of opicapone on levodopa pharmacokinetics in patients with fluctuating Parkinson’s disease. Mov. Disord. 2022 37 11 2272 2283 10.1002/mds.29193 36054562
    [Google Scholar]
  23. Boudíková B. Szumlanski C. Maidak B. Weinshilboum R. Human liver catechol-O-methyltransferase pharmacogenetics. Clin. Pharmacol. Ther. 1990 48 4 381 389 10.1038/clpt.1990.166 2225698
    [Google Scholar]
/content/journals/cn/10.2174/011570159X407015250910194113
Loading
Gender Differences in Efficacy and Tolerability of Opicapone in Add on of Levodopa. A Single-Center Retrospective Cohort Study
Bentham Science Publishers ; https://doi.org/10.2174/011570159X407015250910194113
/content/journals/cn/10.2174/011570159X407015250910194113
/content/journals/cn/10.2174/011570159X407015250910194113
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: opicapone ; Parkinson’s disease ; adverse events ; dyskinesia ; motor complications ; gender differences

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test